MX389073B - Método para producir una proteína de fusión de anticuerpo. - Google Patents
Método para producir una proteína de fusión de anticuerpo.Info
- Publication number
- MX389073B MX389073B MX2019002252A MX2019002252A MX389073B MX 389073 B MX389073 B MX 389073B MX 2019002252 A MX2019002252 A MX 2019002252A MX 2019002252 A MX2019002252 A MX 2019002252A MX 389073 B MX389073 B MX 389073B
- Authority
- MX
- Mexico
- Prior art keywords
- fusion protein
- producing
- column chromatography
- antibody
- fusing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016164901 | 2016-08-25 | ||
| PCT/JP2017/030470 WO2018038243A1 (ja) | 2016-08-25 | 2017-08-25 | 抗体融合蛋白質の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002252A MX2019002252A (es) | 2019-07-04 |
| MX389073B true MX389073B (es) | 2025-03-20 |
Family
ID=61246169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002252A MX389073B (es) | 2016-08-25 | 2017-08-25 | Método para producir una proteína de fusión de anticuerpo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11512135B2 (https=) |
| EP (1) | EP3505538B1 (https=) |
| JP (2) | JP6993814B2 (https=) |
| KR (1) | KR102318480B1 (https=) |
| CN (1) | CN109641971B (https=) |
| AU (1) | AU2017316955B2 (https=) |
| BR (1) | BR112019003622A2 (https=) |
| CA (1) | CA3034589A1 (https=) |
| MX (1) | MX389073B (https=) |
| SG (1) | SG11201901495YA (https=) |
| WO (1) | WO2018038243A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI769982B (zh) | 2015-06-24 | 2022-07-11 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
| US11130815B2 (en) | 2015-06-24 | 2021-09-28 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
| TWI761413B (zh) | 2016-12-26 | 2022-04-21 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體 |
| AU2017385274B2 (en) | 2016-12-26 | 2024-02-22 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein including BDNF |
| KR102655498B1 (ko) | 2017-09-07 | 2024-04-11 | 제이씨알 파마 가부시키가이샤 | 수성 의약 조성물 |
| AU2018345303B2 (en) | 2017-10-02 | 2025-09-18 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| AU2019215782A1 (en) * | 2018-02-05 | 2020-07-16 | Jcr Pharmaceuticals Co., Ltd. | Method for delivering drug to muscle |
| EP3560945A1 (en) * | 2018-04-27 | 2019-10-30 | F. Hoffmann-La Roche AG | Methods for purification of polypeptides using polysorbates |
| WO2019224660A1 (ja) * | 2018-05-24 | 2019-11-28 | ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 | 吸着剤の生産方法 |
| KR102692543B1 (ko) * | 2018-10-26 | 2024-08-07 | 재단법인 목암생명과학연구소 | Ids를 포함하는 융합 단백질 및 이의 용도 |
| PE20231931A1 (es) | 2020-10-14 | 2023-12-01 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas |
| TW202342542A (zh) * | 2020-12-23 | 2023-11-01 | 大陸商廣東菲鵬製藥股份有限公司 | 抗pd-l1抗體、編碼其的核酸、包含其的載體、細胞、藥物組合物及其用途 |
| EP4291246A4 (en) * | 2021-02-11 | 2024-12-11 | Denali Therapeutics Inc. | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF |
| CN116917493A (zh) | 2021-03-09 | 2023-10-20 | Jcr制药股份有限公司 | 抗体-溶酶体酶融合蛋白的制造方法 |
| TW202334428A (zh) * | 2021-12-28 | 2023-09-01 | 日商Ｊｃｒ製藥股份有限公司 | 用於安全的基因治療之抗轉鐵蛋白受體抗體與具有生理活性的蛋白質之融合蛋白質 |
| EP4534677A1 (en) * | 2022-07-08 | 2025-04-09 | JCR Pharmaceuticals Co., Ltd. | Nuecleic acid molecule, vector, recombinant cells, and drug for treating central nervous system diseases |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1871252A (zh) * | 2003-09-05 | 2006-11-29 | Gtc生物治疗学公司 | 在转基因哺乳动物奶中生产融合蛋白的方法 |
| US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| SG158150A1 (en) * | 2004-12-21 | 2010-01-29 | Centocor Inc | Anti-il-12 antibodies, epitopes, compositions, methods and uses |
| WO2008068879A1 (en) | 2006-12-06 | 2008-06-12 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human erythropoietin |
| CN101622274A (zh) * | 2006-12-12 | 2010-01-06 | 比奥雷克西斯药物公司 | 转铁蛋白融合蛋白库 |
| JP2009273427A (ja) | 2008-05-16 | 2009-11-26 | Jcr Pharmaceuticals Co Ltd | 組換え体ヒトｆｓｈの製造方法 |
| EP2350130B1 (en) * | 2008-10-31 | 2018-10-03 | Wyeth LLC | Purification of acidic proteins using ceramic hydroxyapatite chromatography |
| JP2013507131A (ja) * | 2009-10-09 | 2013-03-04 | アーメイゲン・テクノロジーズ・インコーポレイテッド | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| JP6018572B2 (ja) | 2011-01-25 | 2016-11-02 | Ｊｃｒファーマ株式会社 | 組換えヒトイズロン酸−２−スルファターゼの製造方法 |
| WO2012101671A1 (en) | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
| WO2013078562A2 (en) * | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Targeted enzyme compounds and uses thereof |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| WO2014016873A1 (en) * | 2012-07-26 | 2014-01-30 | Jcr Pharmaceuticals Co., Ltd. | Method for production of recombinant human alpha-galactosidase a |
| US9994641B2 (en) | 2013-12-25 | 2018-06-12 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody that passes through blood-brain barrier |
| EP3214172B1 (en) | 2014-10-31 | 2019-02-13 | JCR Pharmaceuticals CO., LTD. | Method for producing remcombinant human dnasei |
| WO2016116966A1 (en) | 2015-01-22 | 2016-07-28 | Jcr Pharmaceuticals Co., Ltd. | Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins |
-
2017
- 2017-08-25 AU AU2017316955A patent/AU2017316955B2/en active Active
- 2017-08-25 JP JP2017161826A patent/JP6993814B2/ja active Active
- 2017-08-25 CN CN201780051299.5A patent/CN109641971B/zh active Active
- 2017-08-25 WO PCT/JP2017/030470 patent/WO2018038243A1/ja not_active Ceased
- 2017-08-25 KR KR1020197007992A patent/KR102318480B1/ko active Active
- 2017-08-25 MX MX2019002252A patent/MX389073B/es unknown
- 2017-08-25 CA CA3034589A patent/CA3034589A1/en active Pending
- 2017-08-25 SG SG11201901495YA patent/SG11201901495YA/en unknown
- 2017-08-25 US US16/327,982 patent/US11512135B2/en active Active
- 2017-08-25 EP EP17843719.0A patent/EP3505538B1/en active Active
- 2017-08-25 BR BR112019003622-9A patent/BR112019003622A2/pt unknown
-
2021
- 2021-12-10 JP JP2021200504A patent/JP7232889B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190040040A (ko) | 2019-04-16 |
| EP3505538A1 (en) | 2019-07-03 |
| AU2017316955B2 (en) | 2022-03-03 |
| JP2022028959A (ja) | 2022-02-16 |
| JP6993814B2 (ja) | 2022-01-14 |
| US20190225700A1 (en) | 2019-07-25 |
| KR102318480B1 (ko) | 2021-10-28 |
| CN109641971B (zh) | 2023-04-04 |
| EP3505538A4 (en) | 2020-03-18 |
| AU2017316955A1 (en) | 2019-03-21 |
| MX2019002252A (es) | 2019-07-04 |
| US11512135B2 (en) | 2022-11-29 |
| BR112019003622A2 (pt) | 2019-05-21 |
| EP3505538B1 (en) | 2024-05-01 |
| JP2018033454A (ja) | 2018-03-08 |
| CA3034589A1 (en) | 2018-03-01 |
| CN109641971A (zh) | 2019-04-16 |
| WO2018038243A1 (ja) | 2018-03-01 |
| JP7232889B2 (ja) | 2023-03-03 |
| SG11201901495YA (en) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389073B (es) | Método para producir una proteína de fusión de anticuerpo. | |
| EA201991976A1 (ru) | Метаболически оптимизированная клеточная культура | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| MX2019002498A (es) | Metodos y productos para la expresion de proteinas en celulas. | |
| EP4148121A3 (en) | Cell-controlled perfusion in continuous culture | |
| EP3539982A3 (en) | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor | |
| PH12020550927A1 (en) | Therapeutic enzyme fusion protein having novel structure and use thereof | |
| EA201492185A1 (ru) | Способ получения рекомбинантной идуронат-2-сульфатазы | |
| WO2019014310A8 (en) | Biological methods for preparing terpenes | |
| MX2020003798A (es) | Metodos para la purificacion de arilsulfatasa a. | |
| ZA202306500B (en) | Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins | |
| EA201492177A1 (ru) | Очистка идуронат-2-сульфатазы | |
| PH12016502406A1 (en) | Cell culture process for producing a protein | |
| BR112016012229A2 (pt) | métodos de produção de polipeptídeos | |
| MX389841B (es) | Proteinas inmovilizadas y uso de las mismas. | |
| PH12020500054A1 (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| MX2018004580A (es) | Metodo para producir proteina de fusion con dominio fc de igg. | |
| ZA200901825B (en) | Split-core-particles for the presentation of foreign molecules, especially for vaccine applications, and method for their production | |
| BR112023018268A2 (pt) | Método para produzir uma proteína de fusão | |
| AR097805A1 (es) | Células de cambio de temperatura para la expresión de alto rendimiento de polipéptidos en levadura y otros transformados | |
| EA201000945A1 (ru) | Конструирование системы секреции на основе sm-белков | |
| MX395311B (es) | Metodo para producir factor de crecimiento de hepatocitos (hgf) activo. | |
| EA200900984A1 (ru) | Улучшение клеточного роста | |
| WO2019183358A3 (en) | Whole cell processes to produce nitroaromatics | |
| WO2010082097A3 (pt) | Proteínas de fusão, processo para a sua preparação e sua utilização em sistemas de expressão de proteínas recombinantes |